Literature DB >> 19125018

Sequence-based advances in the definition of cancer-associated gene mutations.

Andrew J G Simpson1.   

Abstract

PURPOSE OF REVIEW: Recent rapid progress in DNA sequencing has permitted projects to be undertaken that are aimed at building unbiased genome-wide portraits of the underlying mutations in human tumors. This review sets out the highlights of the recent progress in this area and the rapidly evolving picture of the underlying genetic basis of human epithelial cancers. RECENT
FINDINGS: Individual tumors are estimated to contain around 80 point mutations in protein coding genes of which 15 are likely to be tumorigenic. It is likely that there are hundreds of different genes that when mutated contribute to human tumorigenesis most in only a small fraction of tumors. Mutations caused by large chromosomal rearrangements also appear to be common in tumors. In prostate and lung cancers, recurrent chromosomal translocations resulting in tumorigenic fusion proteins have been identified.
SUMMARY: The multitude of new mutated genes being identified in human tumors represent many new directions for experimental research into the molecular pathways that lead to tumor formation. These studies, in turn, are likely to lead to many novel approaches to targeted therapy useful in subsets of tumors with particular types of gene mutation.

Entities:  

Mesh:

Year:  2009        PMID: 19125018     DOI: 10.1097/CCO.0b013e32831de4b9

Source DB:  PubMed          Journal:  Curr Opin Oncol        ISSN: 1040-8746            Impact factor:   3.645


  2 in total

1.  Accumulation of driver and passenger mutations during tumor progression.

Authors:  Ivana Bozic; Tibor Antal; Hisashi Ohtsuki; Hannah Carter; Dewey Kim; Sining Chen; Rachel Karchin; Kenneth W Kinzler; Bert Vogelstein; Martin A Nowak
Journal:  Proc Natl Acad Sci U S A       Date:  2010-09-27       Impact factor: 11.205

Review 2.  New tools for functional genomic analysis.

Authors:  Xin Chen; Eric Jorgenson; Siu Tim Cheung
Journal:  Drug Discov Today       Date:  2009-05-27       Impact factor: 7.851

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.